The Gory Details on DepoMed's Double Miss
DepoMed (NAS: DEPO) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), DepoMed missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. GAAP loss per share dropped.
Gross margins contracted, operating margins grew, net margins grew.
DepoMed reported revenue of $26.2 million. The four analysts polled by S&P Capital IQ expected sales of $28.3 million on the same basis. GAAP reported sales were 55% higher than the prior-year quarter's $16.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.10. The four earnings estimates compiled by S&P Capital IQ anticipated -$0.06 per share. GAAP EPS were -$0.10 for Q1 against -$0.16 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 94.3%, 260 basis points worse than the prior-year quarter. Operating margin was -21.1%, much better than the prior-year quarter. Net margin was -20.9%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $31.1 million. On the bottom line, the average EPS estimate is -$0.01.
Next year's average estimate for revenue is $128.4 million. The average EPS estimate is -$0.02.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 225 members out of 243 rating the stock outperform, and 18 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give DepoMed a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DepoMed is buy, with an average price target of $9.13.
- Add DepoMed to My Watchlist.
The article The Gory Details on DepoMed's Double Miss originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.